Elsevier

Journal of Nuclear Cardiology

Volume 11, Issue 2, March–April 2004, Pages 171-185
Journal of Nuclear Cardiology

Major achievements in nuclear cardiology: III
Prognostic value of gated myocardial perfusion SPECT

https://doi.org/10.1016/j.nuclcard.2003.12.004Get rights and content

Section snippets

Estimating risk versus disease

Although the focus of the current review is the estimation of prognosis with gated myocardial perfusion SPECT, recent evidence has been synthesized to reveal that gated myocardial perfusion SPECT is a highly sensitive test for the detection of a critical stenosis.5 In a recent meta-analysis organized by the United Kingdom's National Institute of Clinical Excellence, diagnostic sensitivity for myocardial perfusion imaging was 87% (n = 2,971/3,425).5 Specificity was lower (73%; n = 772/1,055) but

SPECT risk markers serve as intermediate outcome measures

Thus a shift in publications from diagnostic to prognostic accuracy should be considered a tremendous advance to the field and has the benefit of coordinating outcome estimation with therapeutic randomized controlled trial data. For example, one of our greatest prognosticators in cardiovascular medicine is left ventricular ejection fraction, which is commonly estimated by gated SPECT and is inversely related to cardiac survival. Integrative management decisions can be effectively initiated

Risk thresholds

One of the clear benefits of using risk estimation is that it can be coordinated within population-based risk thresholds. We do know that the underlying risk in the population varies with a patient's pretest risk, such that patients without coronary disease have lower rates of coronary disease events than those with disease (ie, approximately 1% vs 2%, on average). Population risk in those without disease may be estimated by use of one of many global risk scores (eg, Framingham risk32). In a

Bayesian theory

As evidenced by the prior discussion, optimal candidate selection depends on an understanding of the underlying risk in any given patient group. Extending this reasoning one additional step, appropriate patient selection for nuclear imaging will guide the added or incremental value of imaging in any pretest risk cohort. That is, by integrating risk factor, age, and symptom data into a global risk score (eg, Framingham risk score, European risk score), a patient's pretest risk may be estimated

Defining the effectiveness of cardiac imaging principles of risk stratification

A critical step in evaluating the utility of an imaging test is its impact on patient outcome and alterations in patient management.37 The evaluation of a test's ability to risk-stratify individuals has been proposed as an alternative to the challenges of assessing diagnostic accuracy.38 For any given test, risk stratification may be used as a method for defining high- and low-risk cohorts where treatment is allocated to those in greatest need.8 Furthermore, the intensity of management is

Outcome measures

The broad range of outcome measures that are applicable to the use of risk stratification include (1) intermediate clinical outcomes (eg, disease detected, cardiac event predicted), (2) major adverse cardiovascular events (eg, survival rates), (3) cumulative effects of test-driven strategy (eg, life years saved), (4) patient assessment of a test's value (eg, quality of life, patient preferences), and (5) combined quantity- and quality-of-life years (eg, quality-adjusted life years, healthy-year

Defining the interactive nature of risk with predictive models

Risk stratification may be defined statistically as the relative risk ratio (often with 95% CIs), in which a high-risk cohort is calculated as the ratio of increased risk of events. Relative risk ratios indicate the x-fold increase in event risk in high- versus low-risk patients where a statistical increase is noted when the CIs do not include 1.0. As cardiovascular risk is often interactive, additive, or multiplicative, multivariable regression models help to define the independent

Defining the added value of SPECT

The supportive rationale for the use of imaging is that symptoms, established risk factors, physical examination, and functional status measures are often insensitive to disease states.51 SPECT's incremental value may be calculated by quantifying the amount of added information, often called the test's incremental value. In general, tests that provide more added information would be favored over those that have less prognostic content. Diagnosis costs can be high when tests add little value

Concepts in linking risk assessment to tailored medical intervention

SPECT imaging provides not only information about the physiologic significance of flow-limiting disease and left ventricular function but also a global estimation of risk for major adverse cardiac events. As this is the threshold for evidence-based practice, gated SPECT is the tool optimally suited to provide information to guide patient management decisions. This concept, in terms of evidence-based medicine, is called empiric risk stratification, in which optimal improvement in outcome is

Risk of events in patients with normal or low-risk findings

By definition, principles of risk stratification would define a cohort with improved outcome (ie, low risk) and exhibit a clear separation in risk between higher-risk subsets of the population. In the case of patients with normal perfusion findings, numerous studies over the past decade have reported uniformly low rates of major adverse cardiac outcomes. Table 1 details the current evidence in 19 published series on normal or low-risk myocardial perfusion SPECT.8, 33, 54, 55, 56, 57, 58, 59, 60

Risk of events in patients with abnormal myocardial perfusion SPECT results

In the setting of moderate-severely abnormal myocardial perfusion SPECT, rates of “hard” cardiac events, notably cardiac death and nonfatal myocardial infarction, increase logarithmically over and above patients with low-risk findings. As previously noted, the relative increase (ie, x-fold) in risk is commonly calculated by use of a relative risk ratio. On average, relative risk ratios are increased 5- to 7-fold, with the results being highly dependent on the available sample size.8 In larger

Risk of events by poststress measures of left ventricular function

Although nuclear cardiology has been capable of obtaining measures of left ventricular function by first-pass and gated techniques for a number of decades, today rest and poststress estimations of systolic function are frequently performed as gated SPECT imaging. Estimates of left ventricular dysfunction are perhaps one of our greatest known prognosticators in cardiovascular medicine. In this era of gated SPECT imaging, a number of recent reports have provided an estimate of the current

Integrative management approaches

One of the benefits of the wealth of evidence on prognosis with SPECT imaging is that the data can be easily integrated into risk-based patient management algorithms. There are several examples of risk-based algorithms that have been developed in certain patient cohorts. For example, a recent taskforce of the American Society of Nuclear Cardiology has published an evidence-based guideline for at-risk women focusing on selecting candidates who receive the greatest incremental value from referral

High-risk findings and high-risk patient subsets

A review of evidence suggests that high-risk findings on SPECT imaging include patients whose expected rate of major adverse cardiac events is 3% to 5% or more and patients with moderately to severely abnormal perfusion abnormalities, multivessel perfusion abnormalities, or a summed stress score greater than 8. Patients with a high-risk poststress left ventricular ejection fraction lower than 45% are at an elevated risk of major adverse cardiac events. Other high-risk markers include transient

Optimal referral candidates based on added risk effectiveness

Although this review has focused on risk assessment in suspected or known coronary disease, there are specific subsets of patients for whom risk assessment is particularly valuable, with abundant evidence, including diabetics,75, 81, 91, 107, 108 women,109, 110 and patients referred to pharmacologic stress imaging.53, 55, 63, 67, 68, 69, 71, 72, 75, 78, 80, 82, 83, 85, 92 Figure 4 depicts a synthesis of evidence on the prognostic value of myocardial perfusion SPECT by sex and diabetes

Future applications of outcomes assessment in nuclear cardiology

Although the paradigm of estimating risk has added tremendous value to the use of nuclear imaging in guiding patient management decisions, its concept is largely based on the principle of defining the natural history of myocardial perfusion and ventricular function abnormalities. That is, we have defined SPECT risk markers as being associated with major adverse event rates of 4.8% to 8.5% (25th to 75th percentile) per year.50, 53, 57, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75,

Conclusion

This review provides a synopsis of available evidence on the prognostic value of gated myocardial perfusion SPECT. The magnitude of this evidence provides substantial documentation as to the maturity of this modality. As reported in 39 peer-reviewed articles, there is a clear separation in risk of major adverse cardiac events between patients with low- and high-risk perfusion imaging results over the ensuing 2 to 4 years of follow-up. From a total of 69,655 patients (including duplicates), the

Acknowledgements

The authors have indicated they have no financial conflicts of interest.

First page preview

First page preview
Click to open first page preview

References (122)

  • H.C. Lewin et al.

    Achieving sustained improvement in myocardial perfusionrole of isosorbide mononitrate

    Am J Cardiol

    (1997)
  • J.J. Mahmarian et al.

    High reproducibility of myocardial perfusion defects in patients undergoing serial exercise thallium-201 tomography

    Am J Cardiol

    (1995)
  • R.G. Schwartz et al.

    Prospective serial evaluation of myocardial perfusion and lipids during the first six months of pravastastin therapycoronary artery disease regression single photon emission computed tomography monitoring trial

    J Am Coll Cardiol

    (2003)
  • R.C. Pasternak et al.

    Taskforce #1—identification of coronary heart disease riskis there a detection gap?

    J Am Coll Cardiol

    (2003)
  • R.E. Shaw et al.

    Development of a risk adjustment mortality model using the American College of Cardiology—National Cardiovascular Data Registry (ACC-NCDR) experience1998-2000

    J Am Coll Cardiol

    (2002)
  • L.J. Shaw et al.

    A primer of biostatistic and economic methods for diagnostic and prognostic modeling in nuclear cardiologypart II

    J Nucl Cardiol

    (1997)
  • L. Goldman et al.

    The changing “natural history” of symptomatic coronary artery diseasebasis versus bias

    Am J Cardiol

    (1983)
  • M.S. Lauer et al.

    Cause of death in clinical researchtime for a reassessment?

    J Am Coll Cardiol

    (1999)
  • L.A. Diaz et al.

    Independent contribution of myocardial perfusion defects to exercise capacity and heart rate recovery for prediction of all-cause mortality in patients with known or suspected coronary heart disease

    J Am Coll Cardiol

    (2001)
  • L.J. Shaw et al.

    Noninvasive strategies for the estimation of cardiac riskan observational assessment of outcome in stable chest pain patients

    Am J Cardiol

    (2000)
  • A. Elhendy et al.

    Long-term prognosis after a normal exercise stress Tc-99 sestamibi SPECT study

    J Nucl Cardiol

    (2003)
  • R. Hachamovitch et al.

    Determinants of risk and its temporal variation in patients with normal stress myocardial perfusion scanswhat is the warranty period of a normal scan?

    J Am Coll Cardiol

    (2003)
  • P.B. Gibson et al.

    Low event rate for stress-only perfusion imaging in patients evaluated for chest pain

    J Am Coll Cardiol

    (2002)
  • A.R. Galassi et al.

    Incremental prognostic value of technetium-99m-tetrofosmin exercise myocardial perfusion imaging for predicting outcomes in patients with suspected or known coronary artery disease

    Am J Cardiol

    (2001)
  • R.G. Groutars et al.

    Prognostic value and quality of life in patients with normal rest thallium-201/stress technetium 99m-tetrofosmin dual-isotope myocardial SPECT

    J Nucl Cardiol

    (2000)
  • P. Soman et al.

    The prognostic value of a normal Tc-99m sestamibi SPECT study in suspected coronary artery disease

    J Nucl Cardiol

    (1999)
  • A. Alkeylani et al.

    Influence of race on the prediction of cardiac events with stress technetium-99m sestamibi tomographic imaging in patients with stable angina pectoris

    Am J Cardiol

    (1998)
  • T.S. Boyne et al.

    Predicting adverse outcome with exercise SPECT technetium-99m sestamibi imaging in patients with suspected or known coronary artery disease

    Am J Cardiol

    (1997)
  • C.E. Snader et al.

    Importance of estimated functional capacity as a predictor of all-cause mortality among patients referred for exercise thallium single-photon emission computed tomographyreport of 3,400 patients from a single center

    J Am Coll Cardiol

    (1997)
  • M.L. Geleijnse et al.

    Prognostic value of dobutamine-atropine stress technetium-99m sestamibi perfusion scintigraphy in patients with chest pain

    J Am Coll Cardiol

    (1996)
  • G.V. Heller et al.

    Independent prognostic value of intravenous dipyridamole with technetium-99m sestamibi tomographic imaging in predicting cardiac events and cardiac-related hospital admissions

    J Am Coll Cardiol

    (1995)
  • A.M. Kamal et al.

    Prognostic value of adenosine single-photon emission computed tomographic thallium imaging in medically treated patients with angiographic evidence of coronary artery disease

    J Nucl Cardiol

    (1994)
  • J. Machecourt et al.

    Prognostic value of thallium-201 single-photon emission computed tomographic myocardial perfusion imaging according to extent of myocardial defect. Study in 1,926 patients with follow-up at 33 months

    J Am Coll Cardiol

    (1994)
  • H.G. Stratmann et al.

    Prognostic value of dipyridamole technetium-99m sestamibi myocardial tomography in patients with stable chest pain who are unable to exercise

    Am J Cardiol

    (1994)
  • A. Elhendy et al.

    Comparison of late outcome in patients with versus without angina pectoris having reversible perfusion abnormalities during dobutamine stress technetium-99m sestamibi single-photon emission computed tomography

    Am J Cardiol

    (2003)
  • A.D. Patel et al.

    Prognostic value of myocardial perfusion imaging in predicting outcome after renal transplantation

    Am J Cardiol

    (2003)
  • M.J. Zellweger et al.

    Long-term outcome of patients with silent versus symptomatic ischemia six months after percutaneous coronary intervention and stenting

    J Am Coll Cardiol

    (2003)
  • D.S. Berman et al.

    Adenosine myocardial perfusion single-photon emission computed tomography in women compared with men. Impact of diabetes mellitus on incremental prognostic value and effect on patient management

    J Am Coll Cardiol

    (2003)
  • A.F. Schinkel et al.

    Incremental value of exercise technetium-99m tetrofosmin myocardial perfusion single-photon emission computed tomography for the prediction of cardiac events

    Am J Cardiol

    (2003)
  • A. Elhendy et al.

    Comparison of late outcome in patients with versus without angina pectoris having reversible perfusion abnormalities during dobutamine stress technetium-99m sestamibi single-photon emission computed tomography

    Am J Cardiol

    (2003)
  • W. Acampa et al.

    Prognostic value of exercise cardiac tomography performed late after percutaneous coronary intervention in symptomatic and symptom-free patients

    Am J Cardiol

    (2003)
  • A. De Lorenzo et al.

    Prevalence and prognostic value of perfusion defects detected by stress technetium-99m sestamibi myocardial perfusion single-photon emission computed tomography in asymptomatic patients with diabetes mellitus and no known coronary artery disease

    Am J Cardiol

    (2002)
  • N. Bravo et al.

    Prognostic value of myocardial perfusion imaging with adenosine triphosphate

    J Nucl Cardiol

    (2002)
  • D.A. Calnon et al.

    Prognostic value of dobutamine stress technetium-99m-sestamibi single-photon emission computed tomography myocardial perfusion imagingstratification of a high-risk population

    J Am Coll Cardiol

    (2001)
  • Y. Cottin et al.

    Long-term prognostic value of 201Tl single-photon emission computed tomographic myocardial perfusion imaging after coronary stenting

    Am Heart J

    (2001)
  • A.M. Amanullah et al.

    Enhanced prognostic stratification of patients with left ventricular hypertrophy with the use of single-photon emission computed tomography

    Am Heart J

    (2000)
  • X. Kang et al.

    Incremental prognostic value of myocardial perfusion single photon emission computed tomography in patients with diabetes mellitus

    Am Heart J

    (1999)
  • R. Hachamovitch et al.

    Incremental prognostic value of adenosine stress myocardial perfusion single photon emission computed tomography and impact on subsequent management in patients with or suspected of having myocardial ischemia

    Am J Cardiol

    (1997)
  • R. Hachamovitch et al.

    Effective risk stratification using exercise myocardial perfusion SPECT in womengender-related differences in prognostic nuclear testing

    J Am Coll Cardiol

    (1996)
  • R. Hachamovitch et al.

    Gender-related differences in clinical management after exercise nuclear testing

    J Am Coll Cardiol

    (1995)
  • Cited by (0)

    View full text